Central Pacific Bank Trust Division Has $39,000 Position in STERIS plc (NYSE:STE)

Central Pacific Bank Trust Division boosted its position in shares of STERIS plc (NYSE:STE) by 65.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 192 shares of the medical equipment provider’s stock after purchasing an additional 76 shares during the quarter. Central Pacific Bank Trust Division’s holdings in STERIS were worth $39,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of STE. Bleakley Financial Group LLC raised its position in shares of STERIS by 8.7% during the third quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock worth $407,000 after acquiring an additional 134 shares during the last quarter. Franklin Resources Inc. increased its position in STERIS by 171.2% in the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock worth $191,370,000 after purchasing an additional 529,308 shares during the period. Assetmark Inc. increased its position in STERIS by 24.6% in the third quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock worth $3,252,000 after purchasing an additional 2,647 shares during the period. KBC Group NV raised its holdings in STERIS by 52.0% during the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock worth $2,928,000 after purchasing an additional 4,132 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in STERIS during the 3rd quarter valued at about $9,949,000. 94.69% of the stock is currently owned by institutional investors.

STERIS Stock Performance

Shares of STERIS stock opened at $204.12 on Monday. The stock’s fifty day simple moving average is $215.22 and its 200 day simple moving average is $225.47. The company has a current ratio of 2.41, a quick ratio of 1.55 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.15 billion, a PE ratio of 46.60 and a beta of 0.83. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business posted $2.03 EPS. STERIS’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, research analysts predict that STERIS plc will post 9.1 EPS for the current year.

STERIS Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 19th. Investors of record on Tuesday, November 19th were issued a dividend of $0.57 per share. The ex-dividend date of this dividend was Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.12%. STERIS’s payout ratio is 52.05%.

Insider Activity at STERIS

In related news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the sale, the senior vice president now owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on STE shares. StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and upped their target price for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Monday, November 18th. Finally, Stephens reissued an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, STERIS currently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.